Frontlight ResearchEarly access
Taking peoplePhase 4
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Key facts
- Who runs it
- Melbourne Health
- Where
- Australia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 100 people, planned
- Started
- 1 Aug 2019
- Planned end
- 30 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Posaconazole pharmacokinetics
- Record updated
- 28 February 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care
- Able to give informed consent
Who cannot take part
- Unable to give informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.
The group in the trial
- Posaconazole prophylaxisTreatment being tested
Blood samples will be taken from participants undergoing cancer treatment and receiving Posaconazole prophylaxis. The samples will be used for Posaconazole pharmacokinetics study.
Treatment: Posaconazole pharmacokinetics
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection
- Record updated
- 28 February 2025